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Abstract
Background: Mindfulness-based interventions, modified and shortened versions of meditation teachings, have
proved to be effective in the improvement of quality of life in many clinical conditions, including chronic diseases.
Preliminary results available in the literature and in clinical experience indicate a high potential for this treatment
for the reduction of psychological suffering in people with chronic diseases.
Methods/Design: This randomized controlled trial will investigate the impact of a multiple sclerosis (MS) specific
telemedicine meditation intervention on the quality of life of people with multiple sclerosis and their caregivers.
This trial will recruit 120 patients, men and women, with a diagnosis of relapsing-remitting or secondary progressive
MS and their caregivers to participate in a 2-month intervention. Patients will undergo assessments of quality of life,
anxiety, depression, quality of sleep, mindfulness and fatigue levels conducted at baseline, at week 8 (conclusion of
the intervention) and at week 27 (6 months follow-up). Caregivers will complete assessments conducted at the
same time for the same areas, plus caregiver burden. The intervention condition will consist of 2 hours/week of
online meditation in a group setting led by a trainer, plus 1 hour/week of individual exercises. The control
condition will incorporate a psycho-education online program and will require the same contact time commitment
as the intervention condition.
Discussion: Primary outcome measures will consist of assessments of quality of life, anxiety, and depression level.
Assessments of mindfulness level, quality of sleep and fatigue level will be considered secondary outcome
measures.
This investigation will increase understanding of the role of meditation as part of a treatment plan for people with
MS and their caregivers. Overall, this study design has the potential to lead to effective meditation intervention
strategies for this population and improve their quality of life.
Trial registration: Clinical Trials Register NCT02364505. https://clinicaltrials.gov/ct2/show/NCT02364505
Keywords: meditation, mindfulness, multiple sclerosis, telemedicine
* Correspondence: cesare.cavalera@gmail.com
1Department of Psychology, Catholic University of the Sacred Heart of Milan,
via Nirone 15 – 20123, Milan, Italy
Full list of author information is available at the end of the article
© 2016 Cavalera et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Cavalera et al. Trials  (2016) 17:4 
DOI 10.1186/s13063-015-1136-9
Background
Multiple sclerosis (MS) is a chronic disease of the central
nervous system that results in worse quality of life than
that experience by persons living with other chronic dis-
eases [1]. The unpredictable and variable nature of MS
makes it particularly difficult to accept; moreover, the grim
prognosis and the added unpredictability of day-to-day
health in relapse-remitting MS and side effects of medica-
tion [2] greatly impact quality of life and quality of sleep.
Fatigue, anxiety, and depressive features are often reported
by people who have MS [3–5]. In particular, lifetime
prevalence of major depressive disorder is approximately
50 % [6]. Moreover, the impact of care for this kind of dis-
ease on family caregivers can be very high: caregivers often
suffer from sleeplessness, fatigue, anxiety, depression, and
impaired immunological responses [7].
Psychological interventions may be effective in the re-
duction of distress, anxiety, and depression, also reducing
MS symptoms [8], but further exploration is required.
Meditation teachings have proved effective in the im-
provement of quality of life in many clinical conditions
[9–11], including chronic diseases [12, 13], although
accessing it is a challenge for a part of the population
[14, 15]. In a previous study, the use of a standard
meditation protocol was found to promote an improve-
ment in psychological well-being of people with MS [16].
Patients with MS who were assigned to meditation condi-
tion experience an improved quality of life, and reduced
levels of fatigue and depression up to 6 months after the
intervention. Study limits included the fact that the proto-
col was designed for the general population, not for the
clinical peculiarities experienced by people with MS. More-
over, the clinical needs and problems of these people might
prevent full participation in meetings. Lastly, MS caregivers
may benefit from this treatment, but neither this study, nor
any other study, has yet explored this option in depth.
Available data suggest a relevant clinical potential for
an online meditation treatment for people with MS and
their caregivers. While treatments provided through
technological platforms (telemedicine in particular) have
been developed for other populations in recent years
[17], few MS-related programs take advantage of the
internet and related telecommunication platforms. Some
promising efforts have begun: results from a recent pilot
study [18] suggested that a problem-solving 5-week
internet-based self-help program benefited MS patients
with depressive symptoms.
Aims
The main study aims are as follows:
1. To create and test a multimedia software that can
teach meditation at home, following the specific
requirements of people with MS.
2. To investigate the effects of this telemedicine
mindfulness training on the improvement of quality
of life of MS caregivers. While protocol changes will
be made according to MS peculiarities, the resulting
protocol will also be suitable for healthy populations,
including MS caregivers.
3. To assess whether patients undergoing this
meditation protocol show a change in their sleep




The study design of the randomized controlled trial is
composed of two arms (experimental and control groups,
both of 8 weeks duration) and three assessments (2 × 3
design): baseline, directly after treatment, and 6-months
follow-up. Each participant will provide informed consent.
Ethical committees from both the Catholic University of
Milan (reference 19-12-2013) and the Fondazione Don
Gnocchi (reference FDG_9.4.14) have approved the pro-
ject. Results will be published in both scientific and
general-audience media.
Meditation and control protocols and software
development
The first part of the project is dedicated to the adaptation
of the meditation protocol to MS requirements and clin-
ical peculiarities, the creation of the software, and a testing
phase. To maximize its effectiveness [19], the meditation
protocol will consider the potential impact of MS symp-
toms (e.g., numbness, fatigue, tingling), implementing
meaningful changes to be more MS-related than the ori-
ginal mindfulness-based stress reduction protocol, for ex-
ample, by implementing music meditation experiences
and relaxation exercises. The protocol will be imple-
mented using multimedia software, which will provide the
learning and the practice of the intervention. It will be a
course, provided with audio and video stimulations, with
multiple interactions with the trainer. At the same time,
an online control intervention will be implemented. This
control intervention includes a psycho-education online
program about MS, characterized by interviews, practical
advice, and exercises [20]. The contact time commitment
will be the same for both conditions.
Software testing
After the development of the software, it will be tested
for ergonomics and usability. Five patient–caregiver cou-
ples will receive the software and be instructed in its
use. Their qualitative feedback, during the 2 months of
the intervention and afterwards, will be useful in making
changes that could improve the usability and reduce un-
expected events (e.g., code program errors).
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Sample size and recruitment
We aim to recruit 120 people with MS together with
their primary caregivers (therefore, the potential sam-
ple is up to 240 subjects; 120 patients and 120
caregivers).
Inclusion criteria for patients with MS will be:
 Diagnosis of relapsing-remitting or secondary pro-
gressive MS (divided into 60 relapsing-remitting and
60 secondary progressive during the recruitment
procedure);
 Ability to communicate and to understand tasks;
 No change of disease-modifying treatment in the 3
months before the enrolment;
 No clinical relapses or use of steroid treatment
during the 4 weeks before the enrolment;
 Availability of a personal computer, smartphone, or
tablet (compatible with the software);
 Provided informed consent for study participation;
 Age >18 years.
Inclusion criteria for caregivers will be:
 Being a person who lives with the MS patient and
provides him or her with the most care and
assistance;
 Ability to communicate and to understand tasks;
 Availability of a personal computer, smartphone, or
tablet (compatible with the software);
 Provided informed consent for study participation;
 Age >18 years.
Exclusion criteria (referred to both patients and care-
givers) will be:
 Severe co-morbidity that would reduce life expect-
ancy to less than one year (e.g., end-stage onco-
logical diseases or severe cardiac dysfunction);
 Severe neuropsychological impairment (e.g.,
dementia), as indicated by testing below the fifth
percentile in at least 3 of 6 dimensions of
neuropsychological functioning tests (i.e., attention
and concentration, processing speed, executive
function, verbal memory, and verbal processing);
 Psychosis or dissociative disorders;
 Pregnancy.
Subjects will be recruited at the Multiple Sclerosis
Center of the Fondazione Don Gnocchi Hospital, in
Milan.
Procedure
Progression to the study is outlined in Fig. 1.
Screening, assessments, and randomization
Screening will be conducted by doctors of the Multiple
Sclerosis Center of the Fondazione Don Gnocchi Hos-
pital, considering the inclusion and exclusion criteria.
Subsequently all subjects will be fully assessed at base-
line (T1), after 2 months (T2, corresponding to the end
of treatment) and at 6-months follow-up (T3).
Primary outcome measures will assess quality of life,
together with depression and anxiety. Attained mindful-
ness level, quality of sleep, and participation level will be
considered secondary outcome measures. Question-
naires will be self-reported, with online assessments
(therefore accessible from subjects’ own computers).
Subjects will be also assessed, with a qualitative ap-
proach (semi-structured interview), about possible side
effects or adverse events of the treatment, at T2 and T3,
by a psychologist. The interview will be conducted in
person or via teleconference call (e.g., Skype).
Subsequently, randomization will be conducted by the
principal investigator who will be fully blinded to all pa-
tient information, except the study identification num-
bers of patients. Patient–caregiver couples will be
considered as single units for the randomization.
Subjects, consisting of patient–caregiver couples, will
be randomly allocated into two groups (60 patients +
their caregivers for each groups, with a stratification
referred to subjects recruited for the instrumental
assessment):
 Meditation telemedicine intervention, developed and
tested.
 Control group, receiving psycho-education, utilizing
a telemedicine approach.
The intervention phase will begin at the end of the
pilot study (month 6) and will last 11 months.
In the mainframe of the general study, an objective
evaluation of the impact of treatment on sleep disturbance
and fatigue will be conducted with an instrumental assess-
ment. During the software development and testing
phases, we will consecutively recruit 40 subjects with MS
(first recruitment round), with the same inclusion criteria,
who report disturbed sleep. Each of these subjects will
undergo actigraphy. The sensor will be worn by each sub-
ject for two consecutive weeks and will provide objective
information about quality of sleep and daily activity, with
synthetic data summarized by a computer software.
As soon as the intervention phase begins, these 40
subjects will be randomly allocated to one of the two
groups and will undergo all the psychometric assess-
ments, as for the other participants. These subjects will
be assessed by actigraphy again, in a post-intervention
assessment. The method will remain the same, with an
identical timeframe (2 consecutive weeks).
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Measures
Self-report measures
The Multiple Sclerosis Quality of Life-54 questionnaire
is a multidimensional health-related quality of life meas-
ure that combines both generic and MS-specific items in
a single instrument [21]. It is composed of 12 subscales
along with two summary scores, and two additional
single-item measures. The subscales are: physical func-
tion, role limitations, physical, role limitations, emo-
tional, pain, emotional well-being, energy, health
perceptions, social function, cognitive function, health
distress, overall quality of life, and sexual function. The
scale has demonstrated good psychometric properties
and has been translated into Italian [22]. This assess-
ment will be completed only by patients.
The Medical Outcomes Study Short-Form-36 health
survey will be used to assess caregivers’ quality of life.
This is a 36-item scale constructed to survey health
status and quality of life [23], that investigates eight
health aspects: limitations in physical activities be-
cause of health problems; limitations in social activ-
ities because of physical or emotional problems;
limitations in usual role activities because of physical
health problems; bodily pain; general mental health;
limitations in usual role activities because of emo-
tional problems; vitality; general health perceptions. It
is one of the most widely used instruments for the
evaluation of quality of life in many countries in the
world, including Italy [24].
The Hospital Anxiety and Depression Scale will be
used to assess depression and anxiety levels of all the
subjects. This comprises 14 items rated on a four-point
Likert scale [25]. It is designed to screen for the presence
and severity of depression and anxiety in patients with a
physical symptomatology. The scale mainly includes
items that are not related to somatic symptoms of
depression.
The Langer Mindfulness Scale will be used to
assess the level of meditation attunement. This is a
14-item questionnaire that assesses three domains as-
sociated with mindful thinking: novelty seeking, en-
gagement, and novelty producing [26]. An individual
who seeks novelty perceives each situation as an op-
portunity to learn something new. An individual who
scores high in engagement is likely to notice more
details about his or her specific relationship with the
environment.
The Medical Outcomes Study sleep measure will be
used to investigate the quality of sleep [27]. This meas-
ure is composed of ten items, recording on a Likert scale
the frequency of occurrence in the previous 4 weeks of
symptoms and difficulties typically affecting sleep and
daytime activities of patients with chronic illnesses.
Rates of refusal to join the interventions groups after
randomization, as well as drop-out rates, will be
assessed. The software used will keep an access log, re-
cording the number and duration of accesses, together
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Fig. 1 Overview of study procedure
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The psychological assessment phase will begin with
the baseline evaluation, at month 6, with the begin-
ning of the intervention phase. It will last 15 months
(6 months after the end of the recruitment phase, to
allow follow-up assessments).
Sleep and daily activities instrumental assessments
Actigraphy is a non-invasive method of monitoring
cycles of rest and activity; a sensor unit can be worn to
measure gross motor activity. The actigraphic sensor
unit is similar to a watch and continually records
movement.
Analysis
The general linear model will be used to test interaction
effects between treatments (experimental versus control
groups) and over time (three repeated measures). Six
models will be built, one of each primary outcome meas-
ure (quality of life, anxiety, and depression) and separ-
ately for patients and caregivers. Type I error inflation
due to multiplicity of tests will be controlled by the cor-
rection of critical alpha (0.05/6 = 0.008). Violations of
the parametric model assumptions will be tested and ex-
plored with ad-hoc techniques. If violations are detected,
robust methods, data manipulation, or statistical correc-
tions will be applied accordingly. An intention-to-treat
analysis approach will be used. Missing data will be im-
puted with multiple imputation techniques [28]. Accord-
ing to power analysis calculation (G*Power), a total
sample size of 110 patients (and caregivers) will allow
the detection of small interaction effects (η2 = 0.01) with
a 0.85 statistical power, alpha = 0.05 and an assumed
nonsphericity correction (ε) of 0.75. Significant inter-
action effects will be followed by contrast analysis. A
similar analysis will be conducted for the actigraphic
data, with a reduced sample size, enabling the detection
of a small-medium interaction effect under the same
conditions.
The mediation effect of the meditation level will be ex-
amined by adding a within-subjects factor to the general
linear models and the interactions with the treatment
effect will be explored according to the guidelines of
Kraemer et al. [29]. In addition, moderation effects
by sex, age, and number of accesses to the software
will be examined by adding the relative between-
subjects factors into the general linear models and
the interactions with the treatment effect will be ex-
plored according to the same guidelines [29].
Data analysis will be performed with R and SPSS
software.
Data collection and analysis will begin at month 1, and
will last 21 months, 1 month after the last follow-up
data gathered.
Discussion
Consistent with previous efforts that used new technol-
ogy platforms to support psychological interventions
[17, 18], the aim of this study is to investigate the impact
of an MS-specific telemedicine meditation intervention
on the quality of life of people with MS and their care-
givers. Specifically, the main aim of this study is to cre-
ate and test a multimedia software package that can
teach meditation at home, following the specific require-
ments of people with MS, in order to improve quality of
life and quality of sleep and reduce fatigue of patients with
MS and their caregivers. We also aim to gain insight on
the efficacy of a telemedicine meditation intervention on a
range of important outcomes, giving a greater understand-
ing of the underlying processes of change.
We anticipate some study limitations or threats to the
protocol efficacy. The first is related to the virtual nature
of the experience. The online platform could be an ex-
cessively awkward intermediary, and might reduce the
feasibility of the experience compared with meditation
in a group. Moreover, the synchronous communication
that characterizes video-chat interactions could be slo-
wed down by overlapping in turn-taking, or by delays
and problems of internet connections.
Despite possible limits, this study has several key
strengths. It consists of a meditation intervention specif-
ically based on MS features and needs, aimed at improv-
ing the management of MS symptoms, such as
numbness, fatigue, or tingling. The intervention is ad-
dressed not only to patients but also to caregivers, who
may wish to obtain benefits from a meditation interven-
tion. Moreover, the protocol is designed to reduce par-
ticipation barriers, either for practical reasons (e.g., work
activities) or related to physical disabilities that prevent
movement. Finally, the efficacy of the experimental con-
dition is compared with an active intervention (psycho-
education group) to provide a reliable estimation of
changes promoted by this specific intervention, reducing
placebo and Hawthorne effects.
The findings of this study could be most relevant in
improving the quality of life of people with MS and their
caregivers. Scientific literature suggests that meditation
improves the psychological well-being of MS patients
[16]. However, participation in meditation groups can be
hindered for practical reasons (e.g., work activities) or
because of limitations to the physical functions. The
software developed in the project will allow many people
with MS (on a worldwide scale, after language transla-
tions) to access a specific meditation protocol. Moreover,
caregivers of patients with MS often report distress and
psychological suffering. Few studies have investigated
the impact of psychological interventions on them. The
inclusion of caregivers in the protocol allows us to verify
whether this treatment improves their quality of life.
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This intervention has the potential to offer an easy-
access, freely available online resource that can provide
an evidence-based approach to improve quality of life of
people diagnosed with MS and their caregivers. This
protocol describes the development of the interven-
tion and the feasibility of evaluating it using a ran-
domized controlled trial design. If the project’s
hypotheses are confirmed, both patients with MS and
caregivers will be able to use, at their own conveni-
ence, a specific meditation protocol, with a potentially
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